Seattle Genetics Inc (SGEN)

59.04
NASDAQ : Health Care
Prev Close 59.04
Day Low/High 0.00 / 0.00
52 Wk Low/High 26.02 / 75.36
Avg Volume 1.44M
Exchange NASDAQ
Shares Outstanding 141.55M
Market Cap 8.17B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Seattle Genetics Inc. - SGEN

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Seattle Genetics Inc. - SGEN

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Seattle Genetics Inc.

Seattle Genetics Initiates Phase 1 Trial Of SGN-CD352A For Patients With Relapsed Or Refractory Multiple Myeloma

Seattle Genetics Initiates Phase 1 Trial Of SGN-CD352A For Patients With Relapsed Or Refractory Multiple Myeloma

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory...

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Seattle Genetics, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Seattle Genetics, Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Seattle Genetics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Seattle Genetics, Inc. - SGEN

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Seattle Genetics, Inc. - SGEN

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Seattle Genetics, Inc.

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Seattle Genetics, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Seattle Genetics, Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Seattle Genetics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Seattle Genetics, Inc. And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Seattle Genetics, Inc. And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of Seattle Genetics, Inc.

Dow Jones Loses Momentum on March to 20,000 While Nasdaq Hits Record

Dow Jones Loses Momentum on March to 20,000 While Nasdaq Hits Record

The Nasdaq reached a record high at Tuesday's close, but rising consumer confidence and positive housing-market data weren't enough to push the Dow Jones to 20,000.

Dow Retreats from 20,000 Milestone; Stocks Steady as Oil Closes Higher

Dow Retreats from 20,000 Milestone; Stocks Steady as Oil Closes Higher

The Dow's climb to 20,000 stalled Tuesday, but stocks remained somewhat higher. Consumer confidence is increasing, and housing prices are showing positive signs.

Midday Report: Stocks Higher as Consumer Confidence, Housing Prices Rise

Midday Report: Stocks Higher as Consumer Confidence, Housing Prices Rise

Stocks were up midday Tuesday as the Dow moves toward the 20,000 milestone and consumer confidence increases.

Dow Moves Toward 20,000; Stocks Higher as Consumer Confidence Rises

Dow Moves Toward 20,000; Stocks Higher as Consumer Confidence Rises

Stocks were slightly up on Tuesday as the Dow moves toward the 20,000 milestone and consumer confidence increases.

Seattle Genetics Announces Clinical Hold On Several Phase 1 Trials Of Vadastuximab Talirine (SGN-CD33A)

Seattle Genetics Announces Clinical Hold On Several Phase 1 Trials Of Vadastuximab Talirine (SGN-CD33A)

Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that it has received notice from the U.

Stocks Lethargic Near Record Highs

Banks bounced, but transports struggled.

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.

Analysts' Actions -- AIG, Fox, Lululemon, AT&T and More

Analysts' Actions -- AIG, Fox, Lululemon, AT&T and More

Here are Monday's top research calls, including upgrades for AIG, Lululemon Athletica and AT&T, and a downgrade for Twenty-First Century Fox.

Seattle Genetics Highlights Phase 1 Data For Novel Antibody-Drug Conjugate SGN-LIV1A In Patients With Metastatic Breast Cancer At San Antonio Breast Cancer Symposium

Seattle Genetics Highlights Phase 1 Data For Novel Antibody-Drug Conjugate SGN-LIV1A In Patients With Metastatic Breast Cancer At San Antonio Breast Cancer Symposium

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today presented data from an ongoing phase 1 clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with...

Seattle Genetics And Bristol-Myers Squibb Highlight First Data From Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) In Combination With Opdivo (nivolumab) In Relapsed Or Refractory Hodgkin Lymphoma At ASH Annual Meeting

Seattle Genetics And Bristol-Myers Squibb Highlight First Data From Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) In Combination With Opdivo (nivolumab) In Relapsed Or Refractory Hodgkin Lymphoma At ASH Annual Meeting

Seattle Genetics, Inc. (NASDAQ:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today highlighted the first reported data from an ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in...

Seattle Genetics Highlights Long-Term Follow-Up Data From ADCETRIS® (Brentuximab Vedotin) In T-Cell Lymphomas At ASH Annual Meeting

Seattle Genetics Highlights Long-Term Follow-Up Data From ADCETRIS® (Brentuximab Vedotin) In T-Cell Lymphomas At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted long-term follow-up data evaluating ADCETRIS (brentuximab vedotin) in T-cell lymphoma at the 58 th American Society of...

Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy With HMAs, In Patients With Acute Myeloid Leukemia At ASH Annual Meeting

Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy With HMAs, In Patients With Acute Myeloid Leukemia At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted three oral data presentations on vadastuximab talirine (SGN-CD33A; 33A) in patients with acute myeloid leukemia (AML) at the...

Seattle Genetics Presents Phase 1b Data From Vadastuximab Talirine (SGN-CD33A; 33A) In Combination With Standard Of Care In Frontline Acute Myeloid Leukemia At ASH Annual Meeting

Seattle Genetics Presents Phase 1b Data From Vadastuximab Talirine (SGN-CD33A; 33A) In Combination With Standard Of Care In Frontline Acute Myeloid Leukemia At ASH Annual Meeting

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today highlighted phase 1b data evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with the frontline standard of care regimen for...

Seattle Genetics Presents Data From Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline Diffuse Large B-cell Lymphoma At ASH Annual Meeting

Seattle Genetics Presents Data From Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline Diffuse Large B-cell Lymphoma At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today presented data from a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) combination therapy in frontline diffuse large...

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 5, 2016 during the 58th American Society of Hematology (ASH) Annual Meeting in San Diego,...

Seattle Genetics Receives FDA Breakthrough Therapy Designation For ADCETRIS® (Brentuximab Vedotin) In Mycosis Fungoides And Primary Cutaneous Anaplastic Large Cell Lymphoma

Seattle Genetics Receives FDA Breakthrough Therapy Designation For ADCETRIS® (Brentuximab Vedotin) In Mycosis Fungoides And Primary Cutaneous Anaplastic Large Cell Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that the U.